Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group-Reference-Cited by-同舟云学术

Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group

Published:2022-02 Issue: Volume:162 Page:65-75
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Brigitha Leiah J.^ORCID,Fiocco Marta,Pieters Rob,Albertsen Birgitte K.^ORCID,Escherich Gabriele,Lopez-Lopez Elixabet^ORCID,Mondelaers Veerle^ORCID,Vora Ajay^ORCID,Vrooman Lynda,Schmiegelow Kjeld,van der Sluis Inge M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. L-Asparaginase: discovery and development as a tumor-inhibitory agent;Broome;Cancer Treat Rep,1981

2. Use of L-asparaginase in childhood ALL;Muller;Crit Rev Oncol Hematol,1998

3. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase;Pieters;Cancer,2011

4. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study;Avramis;Blood,2002

5. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus;Schmiegelow;Lancet Oncol,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study;Blood Neoplasia;2024-09

2. Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial;Journal of Clinical Oncology;2024-05-10

3. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia;Pharmaceutical Research;2024-03-27

4. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia;Leukemia;2024-01-29

5. Towards development of biobetter: L-asparaginase a case study;Biochimica et Biophysica Acta (BBA) - General Subjects;2024-01